Tuesday, 19 June 2012

Fluarix



influenza virus vaccine

Dosage Form: injection
FULL PRESCRIBING INFORMATION

Indications and Usage for Fluarix


  Fluarix® is indicated for active immunization for the prevention of disease caused by influenza virus subtypes A and type B contained in the vaccine. Fluarix is approved for use in persons 3 years of age and older.



Fluarix Dosage and Administration



Preparation for Administration


Shake well before administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.



Recommended Dose and Schedule


Fluarix should be administered as an intramuscular injection preferably in the region of the deltoid muscle of the upper arm.


 Children: Children 3 years to <9 years of age previously unvaccinated or vaccinated for the first time last season with only one dose receive two 0.5 mL doses; each 0.5 mL dose is administered at least 4 weeks apart.


  Children 3 years to <9 years of age who have been previously vaccinated with 2 doses of any influenza vaccine receive only one 0.5 mL dose.


  Children 9 years of age and older receive only one 0.5 mL dose.


Adults: Administer as a single 0.5 mL dose.


  Do not administer this product intravenously, intradermally, or subcutaneously.


Do not inject in the gluteal area or areas where there may be a major nerve trunk.



Dosage Forms and Strengths


Fluarix is a suspension available in 0.5-mL single-dose prefilled TIP-LOK® syringes.



Contraindications


Do not administer Fluarix to anyone with known systemic hypersensitivity reactions to egg proteins (a vaccine component) or a life-threatening reaction to previous administration of any influenza vaccine [see Description (11)].



Warnings and Precautions



Guillain-Barré Syndrome


  If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Fluarix should be based on careful consideration of the potential benefits and risks.



Latex


The tip caps of the prefilled syringes may contain natural rubber latex which may cause allergic reactions in latex sensitive individuals [see Description (11)].



Altered Immunocompetence


If Fluarix is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons.



Preventing and Managing Allergic Vaccine Reactions


Prior to administration, the healthcare provider should review the patient's immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of Fluarix.



Limitations of Vaccine Effectiveness


Vaccination with Fluarix may not protect all susceptible individuals.



Persons at Risk of Bleeding


  As with other intramuscular injections, Fluarix should be given with caution in individuals with bleeding disorders such as hemophilia or on anticoagulant therapy, to avoid the risk of hematoma following the injection.



Adverse Reactions



Clinical Trials Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice. There is the possibility that broad use of Fluarix could reveal adverse reactions not observed in clinical trials.


Adults: In adults, the most common local adverse reactions and general adverse events observed with Fluarix were pain and redness at the injection site, muscle aches, fatigue, and headache.


Fluarix has been administered to 10,317 adults 18 to 64 years of age and 606 subjects ≥65 years of age in 4 clinical trials.


One of the 4 clinical trials was a randomized, double-blind, placebo-controlled study that evaluated a total of 952 subjects: Fluarix (N = 760) and placebo (N = 192). The population was 18 to 64 years of age (mean 39.1), 54% were female and 80% were white. Solicited events were collected for 4 days (day of vaccination and the next 3 days) (Table 1). Unsolicited events that occurred within 21 days of vaccination (day 0-20) were recorded using diary cards supplemented by spontaneous reports and a medical history as reported by subjects.


Table 1. Percentage of Subjects With Solicited Local Adverse Reactions or General Adverse Events Within 4 Daysa of Vaccination (Total Vaccinated Cohort)




































Fluarix


N = 760


%



Placebo


N = 192


%


Local Adverse Reactions
Pain5512
Redness1810
Swelling96
General Adverse Events
Muscle aches2312
Fatigue2018
Headache1921
Arthralgia66
Shivering33
Fever (≥100.4°F)22

Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available.


a 4 days included day of vaccination and the subsequent 3 days.


Unsolicited adverse events that occurred in ≥1% of recipients of Fluarix and at a rate greater than placebo included upper respiratory tract infection (3.9% versus 2.6%), nasopharyngitis (2.5% versus 1.6%), nasal congestion (2.2% versus 2.1%), diarrhea (1.6% versus 0%), influenza-like illness (1.6% versus 0.5%), vomiting (1.4% versus 0%), and dysmenorrhea (1.3% versus 1.0%).


A randomized, single-blind, active-controlled US study evaluated subjects randomized to receive Fluarix (N = 917) or FLUZONE (N = 910), a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA) stratified by age: 18 to 64 years and ≥65 years of age. In the overall population, 59% of subjects were female and 91% were white. Solicited events were collected using diary cards for 4 days (day of vaccination and the next 3 days) (Table 2). Unsolicited events that occurred within 21 days of vaccination (day 0-20) were recorded using diary cards.


Table 2. Percentage of Subjects With Solicited Local Adverse Reactions or General Adverse Events Within 4 Daysa of Vaccination With Fluarix or Comparator Influenza Vaccine by Age Group (Total Vaccinated Cohort)


























































18-64 Years of Age≥65 Years of Age

Fluarix


N = 315


%

Comparator Influenza Vaccine


N = 314


%

Fluarix


N = 601-602


%

Comparator Influenza Vaccine


N = 596


%
Local Adverse Reactions
Pain48531918
Redness13161113
Swelling91169
General Adverse Events
Fatigue2118910
Headache202188
Muscle aches161377
Arthralgia9965
Shivering3522
Fever (≥99.5°F)3121

Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available.


a 4 days included day of vaccination and the subsequent 3 days.


Unsolicited adverse events that occurred in ≥1% of all recipients of Fluarix or the comparator influenza vaccine in the 21-day post-vaccination period included headache (2.8% versus 2.3%), back pain (1.5% versus 0.4%), pain in extremity (1.2% versus 0.7%), pharyngolaryngeal pain (1.2% versus 0.9%), cough (1.1% versus 0.9%), fatigue (1.1% versus 0.7%), nasopharyngitis (1.0% versus 1.3%), nausea (0.4% versus 1.0%), arthralgia (0.3% versus 1.0%), and injection site pruritus (0.2% versus 1.0%).


A double-blind, placebo-controlled study in subjects 18 to 64 years of age randomized (2:1) to receive Fluarix (N = 5,103) or placebo (N = 2,549) was conducted to evaluate the efficacy of Fluarix. In the total population, 60% were female and 99.9% were white. In a subset (Fluarix [N = 305] and placebo [N = 155]), unsolicited events that occurred within 21 days of vaccination (day 0-20) were recorded on diary cards. The percentage of subjects reporting at least one unsolicited event was similar among the groups (24.3% for Fluarix and 22.6% for placebo). Unsolicited adverse events that occurred in ≥1% of recipients of Fluarix and at a rate greater than placebo included injection site pain (5.2% versus 1.3%), dysmenorrhea (1.3% versus 0.6%), and migraine (1.0% versus 0.0%).


Incidence of Adverse Events Reported in ≥1% of Subjects in Non-US Clinical Trials: The following additional adverse events have been observed in adults in non-US clinical trials with Fluarix. No adverse events were observed at an incidence of >10%.


General Disorders and Administration Site Conditions: Injection site ecchymosis, injection site induration, malaise.


Infections and Infestations: Rhinitis.


Musculoskeletal and Connective Tissue Disorders: Musculoskeletal pain, neck pain.


Skin and Subcutaneous Tissue Disorders: Sweating.


Serious Adverse Events: In the 4 clinical trials in adults (N = 10,923), there was a single case of anaphylaxis reported with Fluarix (<0.01%).


Children: In children 5 years to <18 years of age, the most common (≥10%) local and general adverse events were similar to those in adults but also included swelling at the injection site. In children 3 years to <5 years of age, the most common (≥10%) local and general adverse events included pain, redness, and swelling at the injection site, irritability, loss of appetite, and drowsiness.


A single-blind, active-controlled US study evaluated subjects 6 months to <18 years of age who received Fluarix (N = 2,081) or FLUZONE (N = 1,173), a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA) (Study 005). Children 6 months to <9 years of age with no history of influenza vaccination received 2 doses approximately 28 days apart. Children 6 months to <9 years of age with a history of influenza vaccination and children 9 years of age and older received 1 dose. Children 6 months to <3 years of age received 0.25 mL of Fluarix or comparator influenza vaccine, and children 3 years of age and older received 0.5 mL of Fluarix or comparator influenza vaccine.


Study subjects were 6 months to <18 years of age and 49% were female; 68% were white, 18% were black, 3% were Asian, and 11% were of other racial/ethnic groups.


Solicited local and general adverse events were collected using diary cards for 4 days (day of vaccination and the next 3 days). Unsolicited adverse events that occurred within 28 days of vaccination (day 0-27) after the first vaccination in all subjects and 21 days (day 0-20) after the second vaccination in unprimed subjects were recorded using diary cards.


The frequencies of solicited adverse events for children 3 years to <5 years of age and for children 5 years to <18 years of age were similar for Fluarix and the comparator vaccine (Table 3).


Table 3. Percentage of Subjects With Solicited Local Adverse Reactions or General Adverse Events Within 4 Daysa of First Vaccination With Fluarix or Comparator Influenza Vaccine by Age Group in Children 3 Years to <18 Years of Age









































































Age Group: 3 Years to <5 YearsAge Group: 5 Years to <18 Years

Fluarix


N = 350


%

Comparator Influenza Vaccine


N = 341


%

Fluarix


N = 1,348


%

Comparator Influenza Vaccine


N = 451


%
Local Adverse Reactions
Pain35385656
Redness23201816
Swelling14131413
General Adverse Events
Irritability2122––
Loss of appetite1315––
Drowsiness1320––
Fever7843
Muscle aches––2929
Fatigue––2019
Headache––1516
Arthralgia––66
Shivering––34

a 4 days included day of vaccination and the subsequent 3 days.


In children who received a second dose of Fluarix or the comparator vaccine, the incidences of adverse events following the second dose were similar to those observed after the first dose.


Unsolicited adverse events that occurred in ≥1% of recipients of Fluarix 6 months to <18 years of age included upper respiratory tract infection (5.5%), pyrexia (4.8%), cough (4.7%), vomiting (3.2%), headache (2.8%), rhinorrhea (2.7%), diarrhea (2.5%), pharyngolaryngeal pain (2.4%), nasopharyngitis (2.3%), otitis media (2.0%), nasal congestion (1.8%), upper abdominal pain (1.4%), and upper respiratory tract congestion (1.0%). The incidences of these events were similar in recipients of the comparator vaccine.



Postmarketing Experience


Worldwide voluntary reports of adverse events received for Fluarix since market introduction of this vaccine are listed below. This list includes serious events or events which have causal connection to Fluarix. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.


Blood and Lymphatic System Disorders: Lymphadenopathy.


Cardiac Disorders: Tachycardia.


Ear and Labyrinth Disorders: Vertigo.


Eye Disorders: Conjunctivitis, eye irritation, eye pain, eye redness, eye swelling, eyelid swelling.


Gastrointestinal Disorders: Abdominal pain or discomfort, nausea, swelling of the mouth, throat, and/or tongue.


General Disorders and Administration Site Conditions: Asthenia, chest pain, chills, feeling hot, injection site mass, injection site reaction, injection site warmth, body aches.


Immune System Disorders: Anaphylactic reaction including shock, anaphylactoid reaction, hypersensitivity, serum sickness.


Infections and Infestations: Injection site abscess, injection site cellulitis, pharyngitis, rhinitis, tonsillitis.


Musculoskeletal and Connective Tissue Disorders: Pain in extremity.


Nervous System Disorders: Convulsion, dizziness, encephalomyelitis, facial palsy, facial paresis, Guillain-Barré syndrome, hypoesthesia, myelitis, neuritis, neuropathy, paresthesia.


Respiratory, Thoracic, and Mediastinal Disorders: Asthma, bronchospasm, cough, dyspnea, respiratory distress, stridor.


Skin and Subcutaneous Tissue Disorders: Angioedema, erythema, erythema multiforme, facial swelling, pruritus, rash, Stevens-Johnson syndrome, urticaria.


Vascular Disorders: Henoch-Schönlein purpura, vasculitis.



Adverse Events Associated With Influenza Vaccines


Immediate and presumably allergic reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely occur after influenza vaccination. These reactions probably result from hypersensitivity to certain vaccine components, such as residual egg protein. Although Fluarix contains only a limited quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy [see Contraindications (4)].


The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré syndrome (GBS). Evidence for a causal relation of GBS with subsequent vaccines prepared from other influenza viruses is unclear. If influenza vaccine does pose a risk, it is probably slightly more than 1 additional case/1 million persons vaccinated.


Neurological disorders temporally associated with influenza vaccination such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy have been reported.


Microscopic polyangitis (vasculitis) has been reported temporally associated with influenza vaccination.



Drug Interactions



Concomitant Vaccine Administration


Fluarix should not be mixed with any other vaccine in the same syringe or vial.


There are insufficient data to assess the concurrent administration of Fluarix with other vaccines.



Immunosuppressive Therapies


Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to Fluarix.



USE IN SPECIFIC POPULATIONS



Pregnancy


  Pregnancy Category B


A reproductive and developmental toxicity study has been performed in female rats at a dose approximately 56 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to Fluarix. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Fluarix should be given to a pregnant woman only if clearly needed.


In a reproductive and developmental toxicity study, the effect of Fluarix on embryo-fetal and pre-weaning development was evaluated in pregnant rats. Animals were administered Fluarix by intramuscular injection once prior to gestation, and during the period of organogenesis (gestation days 6, 8, 11, and 15), 0.1 mL/rat/occasion (approximately 56-fold excess relative to the projected human dose on a body weight basis). No adverse effects on mating, female fertility, pregnancy, parturition, lactation parameters, and embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis.



Nursing Mothers


It is not known whether Fluarix is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fluarix is administered to a nursing woman.



Pediatric Use


The immune response of Fluarix has been evaluated in children 6 months to <5 years of age. In a randomized, controlled study, serum hemagglutination-inhibition (HI) antibody titers were lower in children 6 months to <3 years of age compared to a US-licensed vaccine. Immune responses in children 3 years to <5 years of age receiving Fluarix or a US-licensed vaccine have been evaluated [see Clinical Studies (14.2)]. Safety has been evaluated in children 6 months to <18 years of age. The frequencies of solicited adverse events for children 3 years to <5 years of age and for children 5 years to <18 years of age were similar for Fluarix and the comparator vaccine [see Adverse Reactions (6.1)].



Geriatric Use


A randomized, single-blind, active-controlled study evaluated immunological non-inferiority in a cohort of subjects ≥65 years of age who received Fluarix (N = 606) or another US-licensed trivalent, inactivated influenza virus vaccine (N = 604) (Sanofi Pasteur SA). In subjects receiving Fluarix or the comparator vaccine, geometric mean antibody titers post-vaccination were lower in geriatric subjects than in younger subjects (18 to 64 years of age). Fluarix was non-inferior to the comparator vaccine for each of the 3 influenza strains based on mean antibody titers and seroconversion rates. [See Clinical Studies (14.2).] Solicited local and general adverse events were similar for Fluarix and the comparator vaccine among geriatric subjects (Table 2). For both vaccines, the frequency of solicited events in subjects ≥65 years of age was lower than in younger subjects (Table 2). [See Adverse Reactions (6.1).]



Fluarix Description


Fluarix, Influenza Virus Vaccine, for intramuscular injection, is a sterile colorless to slightly opalescent suspension. Fluarix is a vaccine prepared from influenza viruses propagated in embryonated chicken eggs. Each of the influenza viruses is produced and purified separately. After harvesting the virus-containing fluids, each influenza virus is concentrated and purified by zonal centrifugation using a linear sucrose density gradient solution containing detergent to disrupt the viruses. Following dilution, the vaccine is further purified by diafiltration. Each influenza virus solution is inactivated by the consecutive effects of sodium deoxycholate and formaldehyde leading to the production of a “split virus.” Each split inactivated virus is then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The vaccine is formulated from the 3 split inactivated virus solutions.


Fluarix has been standardized according to USPHS requirements for the 2010-2011 influenza season and is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5-mL dose, in the recommended ratio of 15 mcg HA of each of the following 3 strains: A/California/7/2009 NYMC X-181 (H1N1), A/Victoria/210/2009 NYMC X-187 (H3N2) (an A/Perth/16/2009-like virus),and B/Brisbane/60/2008.


Fluarix is formulated without preservatives. Fluarix does not contain thimerosal. Each 0.5-mL dose also contains octoxynol-10 (TRITON® X-100) ≤0.085 mg, α-tocopheryl hydrogen succinate ≤0.1 mg, and polysorbate 80 (Tween 80) ≤0.415 mg. Each dose may also contain residual amounts of hydrocortisone ≤0.0016 mcg, gentamicin sulfate ≤0.15 mcg, ovalbumin ≤0.05 mcg, formaldehyde ≤5 mcg, and sodium deoxycholate ≤50 mcg from the manufacturing process.


The tip caps of the prefilled syringes may contain natural rubber latex. The rubber plungers do not contain latex.



Fluarix - Clinical Pharmacology



Mechanism of Action


Influenza illness and its complications follow infection with influenza viruses. Global surveillance of influenza identifies yearly antigenic variants. For example, since 1977, antigenic variants of influenza A (H1N1 and H3N2) viruses and influenza B viruses have been in global circulation. Specific levels of hemagglutination-inhibition (HI) antibody titer post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the HI antibody titers have been used as a measure of vaccine activity. In some human challenge studies, HI antibody titers of ≥1:40 have been associated with protection from influenza illness in up to 50% of subjects.1,2 Antibody against one influenza virus type or subtype confers little or no protection against another virus. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virological basis for seasonal epidemics and the reason for the usual incorporation of one or more new strains in each year’s influenza vaccine. Therefore, inactivated influenza vaccines are standardized to contain the hemagglutinins of strains (i.e., typically 2 type A and 1 type B), representing the influenza viruses likely to circulate in the United States in the upcoming winter.


Annual revaccination with the current vaccine is recommended because immunity declines during the year after vaccination, and because circulating strains of influenza virus change from year to year.3



Nonclinical Toxicology



Carcinogenesis, Mutagenesis, Impairment of Fertility


Fluarix has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.



Clinical Studies



Efficacy Against Culture-Confirmed Influenza


The efficacy of Fluarix was evaluated in a randomized, double-blind, placebo-controlled study conducted in 2 European countries during the 2006-2007 influenza season. Efficacy of Fluarix, containing A/New Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 influenza strains, was defined as the prevention of culture-confirmed influenza A and/or B cases, for vaccine antigenically matched strains, compared with placebo. Healthy subjects 18 to 64 years of age (mean 39.9 years) were randomized (2:1) to receive Fluarix (N = 5,103) or placebo (N = 2,549) and monitored for influenza-like illnesses (ILI) starting 2 weeks post vaccination and lasting for approximately 7 months. In the overall population, 60% of subjects were female and 99.9% were white. Culture-confirmed influenza was assessed by active and passive surveillance of ILI. Influenza-like illness was defined as at least one general symptom (fever ≥100°F and/or myalgia) and at least one respiratory symptom (cough and/or sore throat). After an episode of ILI, nose and throat swab samples were collected for analysis; attack rates and vaccine efficacy were calculated (Table 4).


Table 4. Attack Rates and Vaccine Efficacy Against Culture-Confirmed Influenza A and/or B in Adults 18 to 64 Years of Age (Total Vaccinated Cohort)











































Attack Rates (n/N)Vaccine Efficacy
Nn%%LLUL
Antigenically Matched Strainsa
Fluarix5,103491.066.9b51.977.4
Placebo2,549742.9–––
All Culture-Confirmed Influenza (Matched, Unmatched, and Untyped)c
Fluarix5,103631.261.6b46.072.8
Placebo2,549823.2–––

aThere were no vaccine matched culture-confirmed cases of A/New Caledonia/20/1999 (H1N1) or B/Malaysia/2506/2004 influenza strains with Fluarix or placebo.


b Vaccine efficacy for Fluarix exceeded a pre-defined threshold of 35% for the lower limit of the 2-sided 95% CI.


c Of the 22 additional cases, 18 were unmatched and 4 were untyped; 15 of the 22 cases were A (H3N2) (11 cases with Fluarix and 4 cases with placebo).


In a post-hoc, exploratory analysis by age, vaccine efficacy (against culture-confirmed influenza A and/or B cases, for vaccine antigenically matched strains) in subjects 18 to 49 years of age was 73.4% (95% CI: 59.3, 82.8) [number of influenza cases: Fluarix (n = 35/3,602) and placebo (n = 66/1,810)]. In subjects 50 to 64 years of age, vaccine efficacy was 13.8% (95% CI: -137.0, 66.3) [number of influenza cases: Fluarix (n = 14/1,501) and placebo (n = 8/739)]. As the study lacked statistical power to evaluate efficacy within age subgroups, the clinical significance of these results is unknown.



Immunological Evaluation


Adults: In a randomized, double-blind, placebo-controlled study conducted in healthy subjects 18 to 64 years of age (mean 39.1 years) in the United States, the immune responses to each of the antigens contained in Fluarix were evaluated in sera obtained 21 days after administration of Fluarix (N = 745) and were compared to those following administration of a placebo vaccine (N = 190). In the overall population, 54% of subjects were female and 80% were white. For each of the influenza antigens, the percentage of subjects who achieved seroconversion, defined as at least a 4-fold increase in serum hemagglutination-inhibition (HI) titer over baseline to ≥1:40 following vaccination, and the percentage of subjects who achieved HI titers of ≥1:40 are presented in Table 5. The lower limit of the 2-sided 95% CI for the percentage of subjects who achieved seroconversion or an HI titer of ≥1:40 exceeded the pre-defined lower limits of 40% and 70%, respectively.


Table 5. Rates With HI Titers ≥1:40 and Rates of Seroconversion to Each Antigen Following Fluarix or Placebo (21 Days After Vaccination) in Adults 18 to 64 Years of Age (ATP Cohort)







































Fluarixa


N = 745


% (95% CI)

Placebo


N = 190


% (95% CI)
% With HI Titers ≥1:40Pre-vaccinationPost-vaccinationPre-vaccinationPost-vaccination
A/New Caledonia/20/99 (H1N1)

54.8


(51.1, 58.4)

96.6


(95.1, 97.8)

52.1


(44.8, 59.4)

51.1


(43.7, 58.4)
A/Wyoming/3/2003 (H3N2)

68.7


(65.3, 72)

99.1


(98.1, 99.6)

65.3


(58, 72)

65.3


(58, 72)
B/Jiangsu/10/2003

49.5


(45.9, 53.2)

98.8


(97.7, 99.4)

48.9


(41.6, 56.3)

51.1


(43.7, 58.4)
SeroconversionbPost-vaccinationPost-vaccination
A/New Caledonia/20/99 (H1N1)59.6 (56, 63.1)0 (0, 1.9)
A/Wyoming/3/2003 (H3N2)61.9 (58.3, 65.4)1.1 (0.1, 3.8)
B/Jiangsu/10/200377.6 (74.4, 80.5)1.1 (0.1, 3.8)

HI = hemagglutination-inhibition; ATP = according-to-protocol; CI = Confidence Interval.


ATP cohort for immunogenicity included subjects for whom assay results were available after vaccination for at least one study vaccine antigen.


a Results obtained following vaccination with Fluarix manufactured for the 2004-2005 season.


bSeroconversion defined as at least a 4-fold increase in serum titers of HI antibodies to ≥1:40.


Non-Inferiority Study: In a randomized, single-blind, active-controlled US study, immunological non-inferiority of Fluarix (N = 923) was compared with FLUZONE (N = 922), a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA). Subjects 18 to 64 years and ≥65 years of age were evaluated for immune responses to each of the vaccine antigens 21 days following vaccination [see Use in Specific Populations (8.5)]. In the overall population, 59% of subjects were female and 91% were white. The co-primary immunogenicity endpoints were geometric mean titers (GMTs) of serum HI antibodies and the percentage of subjects who achieved seroconversion, defined as at least a 4-fold increase in serum HI titer over baseline to ≥1:40, following vaccination. The primary immunogenicity analyses were performed on the According-to-Protocol (ATP) cohort which included all eligible and evaluable subjects with results of at least one serological assay. For each of the influenza antigens, the GMTs and the percentage of subjects who achieved seroconversion are presented in Table 6. Fluarix was non-inferior to the comparator influenza vaccine based on antibody GMTs (upper limit of the 2-sided 95% CI for the GMT ratio [comparator influenza vaccine/Fluarix] ≤1.5) and seroconversion rates (upper limit of the 2-sided 95% CI on difference of the comparator influenza vaccine minus Fluarix ≤10%).


Table 6. Immune Responses 21 Days After Vaccination With Fluarix Compared With Comparator Influenza Vaccine in Adults ≥18 Years of Age (ATP Cohort)










Fluarix


N = 858-866

Comparator


Influenza Vaccine


N = 846-854
GMT (95% CI)Pre-vaccinationPost-vaccinationPre-

Monday, 18 June 2012

Apomorphine Hydrochloride


Class: Nonergot-derivative Dopamine Receptor Agonists
VA Class: CN500
Chemical Name: 5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride
Molecular Formula: C17H17NO2•HCl•½H2O
CAS Number: 41372-20-7
Brands: Apokyn

Introduction

Nonergot-derivative dopamine receptor agonist.1 4


Uses for Apomorphine Hydrochloride


Hypomobility Episodes Associated with Parkinson’s Disease


Acute, intermittent treatment of episodes of hypomobility (i.e., “off” episodes, including end-of-dose “wearing off” and unpredictable “on-off” episodes) associated with advanced Parkinson’s disease (designated an orphan drug by FDA for this use).1 2 3 4 6 5 8 9 11 12 13 14


Used as an adjunct to other antiparkinsonian agents (e.g., levodopa, oral dopamine receptor agonists).1 2 5 8 11


Acute Poisoning


Formerly used to induce vomiting in the early management of acute oral drug overdose and in certain cases of oral poisoning (dose: 5–6 mg sub-Q)†.15


Apomorphine Hydrochloride Dosage and Administration


General



  • Administer an antiemetic (i.e., trimethobenzamide hydrochloride 300 mg orally 3 times daily) beginning 3 days prior to initiation of apomorphine; continue for the first 2 months of therapy or until tolerance to nausea and vomiting develops.1 11




  • Avoid certain other antiemetic agents (i.e., selective 5-HT3 receptor antagonists, dopamine-receptor antagonists [metoclopramide, phenothiazines]).1 4 (See Contraindications under Cautions and Specific Drugs under Interactions.)



Administration


Sub-Q Administration


Administer by sub-Q injection using the dosing pen on an as-needed basis to reverse “off” episodes.1


Administer sub-Q injections in the abdomen, thigh, or upper arm; rotate injection sites.1


Test dose: Administer all test doses in a medical setting where BP can be closely monitored.1 Measure supine and standing BP prior to and 20, 40, and 60 minutes after each test dose.1


Test dose: Determine dose when patient is experiencing an “off” episode.1 Induction of an “off” state can be facilitated by withholding the patient’s antiparkinsonian agents overnight.1


Do not administer IV; possibility of serious adverse effects (e.g., thrombosis, pulmonary embolism).1


Dosage


Available as apomorphine hydrochloride; dosage expressed in terms of the salt.1


Provide dosing instructions for the patient or their caregiver in mL; dose on the dosing pen device is expressed in terms of mL.1


Titrate dose according to patient's response and tolerance.1


Adults


Hypomobility Episodes Associated with Parkinson’s Disease

Sub–Q

Initial test dose is 0.2 mL (2 mg).1 If the 0.2-mL (2-mg) dose is effective and tolerated, this dose may be used on an as-needed, outpatient basis.1 If necessary, the dose may be increased in 0.1-mL (1-mg) increments every few days.1


Patient is not a candidate for apomorphine therapy if clinically significant orthostatic hypotension occurs in response to initial 0.2-mL (2-mg) test dose.1


For patients who tolerate, but do not respond to the initial 0.2-mL (2-mg) test dose, administer a second test dose of 0.4 mL (4 mg) at the next observed “off” period, no sooner than 2 hours after the initial test dose.1 If the 0.4-mL (4-mg) dose is effective and tolerated, a 0.3-mL (3-mg) dose may be used on an as-needed, outpatient basis.1 If necessary, the dose may be increased in 0.1-mL (1-mg) increments every few days.1


For patients who respond, but do not tolerate the 0.4-mL (4-mg) test dose, administer a third test dose of 0.3 mL (3 mg) at the next observed “off” period, but no sooner than 2 hours after the 0.4-mL (4-mg) test dose.1 If the 0.3-mL (3-mg) dose is effective and tolerated, a 0.2-mL (2-mg) dose may be used on an as-needed, outpatient basis.1 If the 0.2-mL (2-mg) dose is tolerated, the dose may be increased, if needed, to 0.3 mL (3 mg) after a few days.1 The dose should not usually be increased to 0.4 mL (4 mg) on an outpatient basis in these patients.1


In clinical studies, most patients responded to doses of 0.3–0.6 mL (3–6 mg); average frequency of dosing was 3 times daily.1


If therapy has been interrupted for >1 week, reinitiate at a dose of 0.2 mL (2 mg) and gradually titrate to effect.1


Prescribing Limits


Adults


Hypomobility Episodes Associated with Parkinson's Disease

Sub-Q

No more than one dose of apomorphine should be administered for treatment of a single “off” episode.1 Safety and efficacy of a second dose during the same hypomobility episode in patients not responding to the initial dose have not been established.1


Doses >0.6 mL (6 mg) not associated with additional therapeutic effect and are not recommended.1


Limited experience with >5 doses per day or daily dosages >2 mL (20 mg).1


Special Populations


Hepatic Impairment


No special recommendations for patients with hepatic impairment.1 (See Hepatic Impairment under Cautions.)


Renal Impairment


In patients with mild or moderate renal impairment, initial test dose and subsequent starting dose is 0.1 mg (1 mg).1


Cautions for Apomorphine Hydrochloride


Contraindications



  • Concomitant use with selective 5-HT3 receptor antagonists.1 (See Specific Drugs under Interactions.)




  • Known hypersensitivity to apomorphine hydrochloride or any ingredient in the formulation (e.g., sodium metabisulfite).1



Warnings/Precautions


Warnings


Administration

Thrombus formation and pulmonary embolism reported following IV administration.1 14 Do not administer IV.1


Nausea and Vomiting

Severe nausea and vomiting expected; concomitant use of an antiemetic recommended.1 Trimethobenzamide was used in clinical studies; other antiemetics are contraindicated (i.e., 5-HT3 receptor antagonists) or not recommended (i.e., dopamine-receptor antagonists).1 (See General under Dosage and Administration and Specific Drugs under Interactions.)


Symptomatic Hypotension

Risk of orthostatic hypotension, hypotension, and/or syncope.1


Whether hypotension contributes to other adverse events (e.g., falls) unknown.1


Prolongation of QT Interval

Possible prolonged QT interval.1 Doses of ≤6 mg are associated with minimal increases in QTc interval.1


Use with caution in patients with congenital or known QT interval prolongation, in those with clinically important bradycardia, in those with uncorrected electrolyte disorders (e.g., hypokalemia, hypomagnesemia), and in those receiving drugs known to prolong the QTc interval.1


Nervous System and Muscular Effects

Risk of falls; may be due to postural and autonomic instability associated with Parkinson’s disease.1 Risk may be increased due to effect of apomorphine on BP and mobility.1


Symptom complex resembling neuroleptic malignant syndrome reported in association with abrupt withdrawal, dosage lowering, or changes in antiparkinsonian therapy.1


Hallucinations

Potential for hallucinations.1


Sudden Sleep Episodes

Falling asleep while engaged in activities of daily living has been reported in patients receiving apomorphine.1 While somnolence occurs frequently in patients receiving apomorphine, these patients perceived no warning signs and believed they were alert immediately prior to the event.1 Many experts believe that falling asleep while engaged in activities of daily living always occurs in a setting of preexisting somnolence, although patients may not give such a history.1


Continually reassess patients for drowsiness or sleepiness.1 Patients may not acknowledge drowsiness or sleepiness until directly questioned about such adverse effects during specific activities.1 Ask patients about any factors that may increase the risk of somnolence (e.g., concomitant sedating drugs, the presence of sleep disorders).1


Apomorphine generally should be discontinued if a patient develops clinically important daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating).1 If the drug is continued, the patients should be advised not to drive and to avoid other potentially dangerous activities.1 Insufficient information to establish whether dosage reduction will eliminate episodes of falling asleep while engaged in activities of daily living.1


Cardiovascular Effects

Risk of angina, MI, cardiac arrest, and/or sudden death.1 Angina and MI occurred in some patients within 2 hours of apomorphine dosing; cardiac arrest and sudden death occurred at times unrelated to dosing.1


May exacerbate coronary and cerebral ischemia due to effects of apomorphine on BP.1 Use with caution in patients with cardiovascular and cerebrovascular disease.1


If signs and symptoms of coronary or cerebral ischemia occur, reevaluate continued use of the drug.1


Injection Site Reactions

Injection site reactions (bruising, granuloma, pruritus) reported.1


Abuse and Misuse Potential

Escalation of apomorphine dose beyond the prescribed frequency reported in patients trying to avoid all symptoms of an “off” episode.1 Hypersexuality and increased erections can occur due to abuse of apomorphine.1 11


Monitor patients for excessive use (e.g., use out of proportion to motor signs).1


Sensitivity Reactions


Sulfite Sensitivity

The commercially available apomorphine hydrochloride injection contains sodium metabisulfite, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.1


General Precautions


Dyskinesia

May cause or exacerbate dyskinesias.1


Cardiorespiratory Fibrosis and Fibrotic Complications

Retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, and cardiac valvulopathy reported in patients receiving ergot-derivative dopamine receptor agonists; presumably related to the ergoline structure of these agents.1 Possible that nonergot-derived drugs that increase dopaminergic activity (e.g., apomorphine) may induce similar changes.1


Priapism

Possible prolonged painful erections.1


Ocular Effects

Retinal degeneration reported in albino rats given dopamine agonists for prolonged periods (usually 2-year carcinogenicity studies); similar changes not observed in albino mice, rats, or monkeys.1 Clinical importance in humans not established; however, effect cannot be disregarded because the presumed mechanism of action may apply to all vertebrates.1


Specific Populations


Pregnancy

Category C.1


Lactation

Not known whether apomorphine is distributed into milk.1 Discontinue nursing or the drug.1


Pediatric Use

Safety and efficacy for hypermobility episodes not established.1


Geriatric Use

Increased incidence of confusion, hallucinations, serious adverse events (life-threatening events or events resulting in hospitalization and/or increased disability), falls, cardiovascular events, respiratory disorders, and GI events in geriatric individuals compared with younger adults.1


Hepatic Impairment

Systemic exposure increased in patients with mild to moderate hepatic impairment; use with caution.1 Not studied in patients with severe hepatic impairment.1 (See Special Populations under Pharmacokinetics.)


Renal Impairment

Dosage adjustment necessary in patients with mild to moderate renal impairment.1 Not studied in patients with severe renal impairment or those undergoing dialysis.1 13 (See Renal Impairment under Dosage and Administration and Special Populations under Pharmacokinetics.)


Common Adverse Effects


Yawning, dyskinesias, nausea and/or vomiting, somnolence, dizziness, rhinorrhea, hallucinations, edema, chest pain, increased sweating, flushing, and pallor.1


Interactions for Apomorphine Hydrochloride


Drugs That Prolong QT Interval


Potential pharmacologic interaction (additive effect on QT interval prolongation).1 (See Prolongation of QT Interval under Cautions.)


Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes


Pharmacokinetic interaction unlikely.1


Specific Drugs
























Drug



Interaction



Comments



Antihypertensive agents and vasodilators



Potential pharmacologic interaction (additive hypotensive effects)1


Concomitant use associated with increased incidence of hypotension, MI, pneumonia, serious falls, bone and joint injuries1



Caution1



Catecho-O-methyltransferase (COMT) inhibitors



Pharmacokinetic interaction unlikely1 7



CNS depressants



Alcohol: Potential pharmacologic interaction (additive sedative and hypotensive effects)1


CNS depressants: Potential pharmacologic interaction (additive sedative effects)1



5-HT3 receptor antagonists (dolasetron, granisetron, ondansetron, palonosetron)



Potential pharmacologic interaction (profound hypotension and loss of consciousness)1



Concomitant use contraindicated1



Dopamine-receptor antagonists (e.g., phenothiazines, butyrophenones, thioxanthenes, metoclopramide)



Potential pharmacologic interaction (reduced efficacy of apomorphine)1



Phenothiazines, butyrophenones, thioxanthenes: Weigh benefits and risks of therapy with a dopamine agonist in patients receiving one of these dopamine-receptor antagonists for the treatment of major psychosis1



Levodopa/carbidopa



Potential pharmacologic interaction (additive neurologic effect; used to therapeutic effect)1


Pharmacokinetic interaction unlikely1


Apomorphine Hydrochloride Pharmacokinetics


Absorption


Bioavailability


Bioavailability following sub-Q administration is 100%.1 Peak plasma concentrations achieved in 10–60 minutes.1


Onset


Following sub-Q administration, therapeutic response usually achieved in 10–20 minutes.1 2 5 8 12


Duration


Approximately 60 minutes.1 2 5 8 12


Special Populations


In individuals with moderate hepatic impairment receiving a single sub-Q dose of apomorphine, peak plasma concentrations and AUC were increased 25 and 10%, respectively, compared with healthy individuals.1


In patients with moderate renal impairment receiving a single sub-Q dose of apomorphine, peak plasma concentrations and AUC were increased 50 and 16%, respectively, compared with healthy individuals.1 Time to peak plasma concentrations was not affected by renal status.1


Distribution


Extent


Maximum cerebrospinal fluid concentrations are <10% of peak plasma concentrations.1


Elimination


Metabolism


Routes of metabolism not known.1 Potential metabolic routes include sulfation, N–demethylation, glucuronidation, and oxidation.1


Half-life


40 minutes.1


Special Populations


Half-life not affected by renal status.1


Stability


Storage


Parenteral


Injection

25°C (may be exposed to 15–30°C).1


ActionsActions



  • Exhibits a higher affinity for dopamine D4 receptors in vitro than for dopamine D2, D3, or D5 receptors.1




  • Appears to act by stimulating postsynaptic dopamine D2 receptors in the caudate-putamen.1



Advice to Patients



  • Importance of taking apomorphine only as prescribed.1




  • Importance of instructing patient and/or caregiver regarding proper dosage and administration of apomorphine, including detailed instruction in the use of the dosing pen, in patients whose clinician has determined that the drug can safely and effectively be self-administered in the patient’s home by the patient, family member, or other responsible individual.1




  • Advise that hallucinations, hypotension, and other adverse effects (e.g., injection site reactions) may occur.1




  • Risk of orthostatic hypotension with or without dizziness, nausea, syncope, or sweating.1 Advise not to rise rapidly after prolonged sitting or lying down, especially during the first few weeks of therapy.1




  • Risk of somnolence and the possibility of falling asleep during activities of daily living; avoid driving or operating machinery until effects on the individual are known.1




  • Importance of informing clinicians if increased somnolence or new episodes of falling asleep during activities of daily living (e.g., watching television, riding in a car as a passenger) occur at any time during apomorphine therapy.1 Patients should not drive or participate in potentially dangerous activities until their clinician has been notified.1




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription (especially selective 5-HT3 receptor antagonists) and OTC drugs, as well as any concomitant illnesses.1




  • Importance of informing patients of other important precautionary information.1 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.













Apomorphine Hydrochloride (Hemihydrate)

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Parenteral



Injection, for sub-Q use only



10 mg/mL



Apokyn (with sodium metabisulfite; benzyl alcohol 0.5% in cartridges)



Mylan



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



1. Mylan Bertek Pharmaceuticals Inc. Apokyn (apomorphine hydrochloride) injection prescribing information. Research Triangle Park, NC; 2004 Apr.



2. Stacy M. Apomorphine: North American clinical experience. Neurology. 2004; 62 (Suppl 4):S18-21. [IDIS 516185] [PubMed 15037667]



3. Dewey RB Jr. Management of motor complications in Parkinson's disease. Neurology. 2004; 62 (Suppl 4):S3-7. [IDIS 516182] [PubMed 15037664]



4. Anon. FDA approves Apokyn for the acute treatment of episodes of immobility in Parkinson’s patients. FDA Talk Paper. Rockville, MD: Food and Drug Administration; 2004 Apr 21.



5. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001; 58:1385-92. [IDIS 518541] [PubMed 11559309]



6. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97 414). Rockville, MD. From FDA website (). Accessed 2004 Aug 16.



7. Zijlmans JCM, Debilly B, Rascol O et. al. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord. 2004; 19:1006-11. [PubMed 15372589]



8. Sherry JH, Guyton PJ, Van Lunen B, Bottini PB. Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease. Neurology. 2003; 60 (Suppl 1): A81.



9. Hughes AJ, Bishop S, Kleedorfer B et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993; 8:165-70. [PubMed 8474483]



10. Food and Drug Administration. Sulfiting agents; labeling in drugs for human use: warning statement. [Docket No. 84N-0113] Fed Regist. 1985; 50:47558-63.



11. Anon. Apomorphine (Apokyn) for advanced Parkinson's disease. Med Lett Drugs Ther. 2005; 47:7-8.



12. Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology. 2004; 62(Suppl 4):S12-7. [IDIS 516184] [PubMed 15037666]



13. Mylan Bertek Pharmaceuticals Inc. Apokyn (apomorphine hydrochloride) monograph. Research Triangle Park, NC; 2004 May 26.



14. Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology. 2004; 62(Suppl 4):S22-6. [IDIS 516186] [PubMed 15037668]



15. AHFS Drug Information 1990. McEvoy, GK, ed. Apomorphine hydrochloride. Bethesda, MD: American Society of Health-System Pharmacists; 1990:1652-3.



16. Mylan Bertek Pharmaceuticals, Overland Park, KS: Personal communication.



More Apomorphine Hydrochloride resources


  • Apomorphine Hydrochloride Side Effects (in more detail)
  • Apomorphine Hydrochloride Use in Pregnancy & Breastfeeding
  • Apomorphine Hydrochloride Drug Interactions
  • Apomorphine Hydrochloride Support Group
  • 4 Reviews for Apomorphine Hydrochloride - Add your own review/rating


  • Apokyn Prescribing Information (FDA)

  • Apokyn Advanced Consumer (Micromedex) - Includes Dosage Information

  • Apokyn MedFacts Consumer Leaflet (Wolters Kluwer)

  • Apokyn Consumer Overview



Compare Apomorphine Hydrochloride with other medications


  • Parkinson's Disease
  • Tardive Dyskinesia

Saturday, 16 June 2012

Miscellaneous uncategorized agents


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

See also

Medical conditions associated with miscellaneous uncategorized agents:

  • Acne
  • Acute Nonlymphocytic Leukemia
  • Amyotrophic Lateral Sclerosis
  • Barium Meal Transit
  • Bleeding Disorder
  • Cardiomyopathy Prophylaxis
  • Chronic Myelogenous Leukemia
  • Diagnosis and Investigation
  • Dupuytren's contracture
  • Extravasation
  • Gallbladder Contraction
  • Granuloma Annulare
  • Hyperammonemia
  • Hypercalcemia of Malignancy
  • Hyperkalemia
  • Hypodermoclysis
  • Melanoma, Metastatic
  • Mucositis
  • Obsessive Compulsive Disorder
  • Pancreatic Secretion
  • Penicillin Sensitization Testing
  • Pityriasis rubra pilaris
  • Porphyria
  • Rosacea
  • Secondary Hyperparathyroidism
  • Subcutaneous Urography
  • Thrombocythemia
  • Urea Cycle Disorders

Drug List:

Thursday, 14 June 2012

Calci Mix


Generic Name: calcium carbonate (KAL see um KAR boe nate)

Brand Names: Alka-Mints, Cal-Gest, Calcarb, Calci Mix, Calci-Chew, Calci-Mix, Calcium Concentrate, Calcium Liquid Softgel, Calcium Oyster Shell, Caltrate, Chooz, Extra Strength Mylanta Calci Tabs, Icar Prenatal Chewable Calcium, Maalox Antacid Barrier, Maalox Childrens', Maalox Quick Dissolve, Maalox Quick Dissolve Maximum Strength, Maalox Regular Strength, Mylanta Child, Nephro Calci, Os-Cal 500, Oysco 500, Oyst Cal 500, Oyster Cal, Oyster Calcium, Oyster Shell, Pepto Children's, Rolaids Sodium Free, Rolaids Soft Chew, Titralac, Tums, Tums 500, Tums E-X, Tums Kids, Tums QuikPak, Tums Ultra


What is Calci-Mix (calcium carbonate)?

Calcium is a mineral that is found naturally in foods. Calcium is necessary for many normal functions of the body, especially bone formation and maintenance. Calcium can also bind to other minerals (such as phosphate) and aid in their removal from the body.


Calcium carbonate is used to prevent and to treat calcium deficiencies.


Calcium carbonate may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Calci-Mix (calcium carbonate)?


Do not take calcium carbonate or antacids that contain calcium without first asking your doctor if you also take other medicines. Calcium can make it harder for your body to absorb certain medicines. Calcium carbonate works best if you take it with food.

What should I discuss with my healthcare provider before taking Calci-Mix (calcium carbonate)?


To make sure you can safely take calcium carbonate, tell your doctor if you have any of these other conditions:



  • a history of kidney stones; or




  • a parathyroid gland disorder.




Talk to your doctor before taking calcium carbonate if you are pregnant. Talk to your doctor before taking calcium carbonate if you are breast-feeding a baby.

How should I take Calci-Mix (calcium carbonate)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.


Calcium carbonate works best if you take it with food. Swallow the calcium carbonate tablet or capsule with a full glass of water.

The chewable tablet should be chewed before you swallow it.


Use the calcium carbonate powder as directed. Allow the powder to dissolve completely, then consume the mixture.


Shake the oral suspension (liquid) well just before you measure a dose. Measure the liquid with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one. Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, vomiting, decreased appetite, constipation, confusion, delirium, stupor, and coma.


What should I avoid while taking Calci-Mix (calcium carbonate)?


Follow your healthcare provider's instructions about any restrictions on food, beverages, or activity.


Calci-Mix (calcium carbonate) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:



  • nausea or vomiting;




  • decreased appetite;




  • constipation;




  • dry mouth or increased thirst; or




  • urinating more than usual.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs can affect Calci-Mix (calcium carbonate)?


Calcium carbonate can make it harder for your body to absorb other medications you take by mouth. Tell your doctor if you are taking:



  • digoxin (Lanoxin, Lanoxicaps);




  • antacids or other calcium supplements;




  • calcitriol (Rocaltrol) or vitamin D supplements; or




  • doxycycline (Adoxa, Doryx, Oracea, Vibramycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).



This list is not complete and other drugs may interact with calcium carbonate. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Calci-Mix resources


  • Calci-Mix Side Effects (in more detail)
  • Calci-Mix Use in Pregnancy & Breastfeeding
  • Calci-Mix Drug Interactions
  • Calci-Mix Support Group
  • 0 Reviews for Calci-Mix - Add your own review/rating


Compare Calci-Mix with other medications


  • Duodenal Ulcer
  • Erosive Esophagitis
  • GERD
  • Hypocalcemia
  • Indigestion
  • Osteopenia
  • Osteoporosis
  • Stomach Ulcer


Where can I get more information?


  • Your doctor or pharmacist can provide more information about calcium carbonate.

See also: Calci-Mix side effects (in more detail)


Marcaine





Dosage Form: injection, solution

Marcaine™


Bupivacaine Hydrochloride Injection, USP


Marcaine™


With Epinephrine 1:200,000 (as bitartrate)


Bupivacaine Hydrochloride and Epinephrine Injection, USP                 Rx only



Marcaine Description


Bupivacaine hydrochloride is 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate, a white crystalline powder that is freely soluble in 95 percent ethanol, soluble in water, and slightly soluble in chloroform or acetone. It has the following structural formula:




Epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl] benzyl alcohol. It has the following structural formula:




Marcaine is available in sterile isotonic solutions with and without epinephrine (as bitartrate) 1:200,000 for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Solutions of Marcaine may be autoclaved if they do not contain epinephrine. Solutions are clear and colorless.


Bupivacaine is related chemically and pharmacologically to the aminoacyl local anesthetics. It is a homologue of mepivacaine and is chemically related to lidocaine. All three of these anesthetics contain an amide linkage between the aromatic nucleus and the amino, or piperidine group. They differ in this respect from the procaine-type local anesthetics, which have an ester linkage.


Marcaine — Sterile isotonic solutions containing sodium chloride. In multiple-dose vials, each mL also contains 1 mg methylparaben as antiseptic preservative. The pH of these solutions is adjusted to between 4 and 6.5 with sodium hydroxide or hydrochloric acid.


Marcaine with epinephrine 1:200,000 (as bitartrate)—Sterile isotonic solutions containing sodium chloride. Each mL contains bupivacaine hydrochloride and 0.0091 mg epinephrine bitartrate, with 0.5 mg sodium metabisulfite, 0.001 mL monothioglycerol, and 2 mg ascorbic acid as antioxidants, 0.0017 mL 60% sodium lactate buffer, and 0.1 mg edetate calcium disodium as stabilizer. In multiple-dose vials, each mL also contains 1 mg methylparaben as antiseptic preservative. The pH of these solutions is adjusted to between 3.4 and 4.5 with sodium hydroxide or hydrochloric acid. The specific gravity of Marcaine 0.5% with epinephrine 1:200,000 (as bitartrate) at 25°C is 1.008 and at 37°C is 1.008.



Marcaine - Clinical Pharmacology


Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch,  (4) proprioception, and (5) skeletal muscle tone.


Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems (CNS). At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Recent clinical reports and animal research suggest that these cardiovascular changes are more likely to occur after unintended intravascular injection of bupivacaine. Therefore, incremental dosing is necessary.


Following systemic absorption, local anesthetics can produce central nervous system stimulation, depression, or both. Apparent central stimulation is manifested as restlessness, tremors and shivering progressing to convulsions, followed by depression and coma progressing ultimately to respiratory arrest. However, the local anesthetics have a primary depressant effect on the medulla and on higher centers. The depressed stage may occur without a prior excited state.


Pharmacokinetics: The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution. A dilute concentration of epinephrine (1:200,000 or 5 mcg/mL) usually reduces the rate of absorption and peak plasma concentration of Marcaine, permitting the use of moderately larger total doses and sometimes prolonging the duration of action.


The onset of action with Marcaine is rapid and anesthesia is long lasting. The duration of anesthesia is significantly longer with Marcaine than with any other commonly used local anesthetic. It has also been noted that there is a period of analgesia that persists after the return of sensation, during which time the need for strong analgesics is reduced.


The onset of action following dental injections is usually 2 to 10 minutes and anesthesia may last two or three times longer than lidocaine and mepivacaine for dental use, in many patients up to 7 hours. The duration of anesthetic effect is prolonged by the addition of epinephrine 1:200,000.


Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug the higher the percentage of drug bound to plasma proteins.


Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by (1) the degree of plasma protein binding, (2) the degree of ionization, and (3) the degree of lipid solubility. Fetal/ maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Marcaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4). The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation.


Depending upon the route of administration, local anesthetics are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain.


Pharmacokinetic studies on the plasma profile of Marcaine after direct intravenous injection suggest a three-compartment open model. The first compartment is represented by the rapid intravascular distribution of the drug. The second compartment represents the equilibration of the drug throughout the highly perfused organs such as the brain, myocardium, lungs, kidneys, and liver. The third compartment represents an equilibration of the drug with poorly perfused tissues, such as muscle and fat. The elimination of drug from tissue distribution depends largely upon the ability of binding sites in the circulation to carry it to the liver where it is metabolized.


After injection of Marcaine for caudal, epidural, or peripheral nerve block in man, peak levels of bupivacaine in the blood are reached in 30 to 45 minutes, followed by a decline to insignificant levels during the next three to six hours.


Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic or renal disease, addition of epinephrine, factors affecting urinary pH, renal blood flow, the route of drug administration, and the age of the patient. The half-life of Marcaine in adults is 2.7 hours and in neonates 8.1 hours.


In clinical studies, elderly patients reached the maximal spread of analgesia and maximal motor blockade more rapidly than younger patients. Elderly patients also exhibited higher peak plasma concentrations following administration of this product. The total plasma clearance was decreased in these patients.


Amide-type local anesthetics such as Marcaine are metabolized primarily in the liver via conjugation with glucuronic acid. Patients with hepatic disease, especially those with severe hepatic disease, may be more susceptible to the potential toxicities of the amide-type local anesthetics. Pipecoloxylidine is the major metabolite of Marcaine.


The kidney is the main excretory organ for most local anesthetics and their metabolites. Urinary excretion is affected by urinary perfusion and factors affecting urinary pH. Only 6% of bupivacaine is excreted unchanged in the urine.


When administered in recommended doses and concentrations, Marcaine does not ordinarily produce irritation or tissue damage and does not cause methemoglobinemia.



Indications and Usage for Marcaine


Marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (See WARNINGS.)


Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of Marcaine in these patients.


Marcaine is not recommended for intravenous regional anesthesia (Bier Block). See WARNINGS.


The routes of administration and indicated Marcaine concentrations are:


∙ local infiltration                                                                                 0.25%


∙ peripheral nerve block                                                                      0.25% and 0.5%


∙ retrobulbar block                                                                              0.75%


∙ sympathetic block                                                                             0.25%


∙ lumbar epidural                                                                                 0.25%, 0.5%, and 0.75%


                                                                                                          (0.75% not for obstetrical anesthesia)


∙ caudal                                                                                               0.25% and 0.5%


∙ epidural test dose                                                                              0.5% with epinephrine 1:200,000


∙ dental blocks                                                                                     0.5% with epinephrine 1:200,000


(See DOSAGE AND ADMINISTRATION for additional information.)


Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of Marcaine.



Contraindications


Marcaine is contraindicated in obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death.


Marcaine is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide-type or to other components of Marcaine solutions.



Warnings




THE 0.75% CONCENTRATION OF Marcaine IS NOT RECOMMENDED FOR OBSTETRICAL ANESTHESIA. THERE HAVE BEEN REPORTS OF CARDIAC ARREST WITH DIFFICULT RESUSCITATION OR DEATH DURING USE OF Marcaine FOR EPIDURAL ANESTHESIA IN OBSTETRICAL PATIENTS. IN MOST CASES, THIS HAS FOLLOWED USE OF THE 0.75% CONCENTRATION. RESUSCITATION HAS BEEN DIFFICULT OR IMPOSSIBLE DESPITE APPARENTLY ADEQUATE PREPARATION AND APPROPRIATE MANAGEMENT. CARDIAC ARREST HAS OCCURRED AFTER CONVULSIONS RESULTING FROM SYSTEMIC TOXICITY, PRESUMABLY FOLLOWING UNINTENTIONAL INTRAVASCULAR INJECTION. THE 0.75% CONCENTRATION SHOULD BE RESERVED FOR SURGICAL PROCEDURES WHERE A HIGH DEGREE OF MUSCLE RELAXATION AND PROLONGED EFFECT ARE NECESSARY.


LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES WHICH MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED, AND THEN ONLY AFTER INSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY RESUSCITATIVE EQUIPMENT, AND THE PERSONNEL RESOURCES NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES. (See also ADVERSE REACTIONS, PRECAUTIONS, and OVERDOSAGE.) DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE, AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH.


Local anesthetic solutions containing antimicrobial preservatives, i.e., those supplied in multiple-dose vials, should not be used for epidural or caudal anesthesia because safety has not been established with regard to intrathecal injection, either intentionally or unintentionally, of such preservatives.


Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.


It is essential that aspiration for blood or cerebrospinal fluid (where applicable) be done prior to injecting any local anesthetic, both the original dose and all subsequent doses, to avoid intravascular or subarachnoid injection. However, a negative aspiration does not ensure against an intravascular or subarachnoid injection.


Marcaine with epinephrine 1:200,000 or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. Likewise, solutions of Marcaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamineoxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result.


Until further experience is gained in pediatric patients younger than 12 years, administration of Marcaine in this age group is not recommended.


Mixing or the prior or intercurrent use of any other local anesthetic with Marcaine cannot be recommended because of insufficient data on the clinical use of such mixtures.


There have been reports of cardiac arrest and death during the use of Marcaine for intravenous regional anesthesia (Bier Block). Information on safe dosages and techniques of administration of Marcaine in this procedure is lacking. Therefore, Marcaine is not recommended for use in this technique.


Marcaine with epinephrine 1:200,000 contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Single-dose ampuls and single-dose vials of Marcaine without epinephrine do not contain sodium metabisulfite.



Precautions




General: The safety and effectiveness of local anesthetics depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. (See WARNINGS, ADVERSE REACTIONS, and OVERDOSAGE.) During major regional nerve blocks, the patient should have IV fluids running via an indwelling catheter to assure a functioning intravenous pathway. The lowest dosage of local anesthetic that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should be used when feasible.



Epidural Anesthesia: During epidural administration of Marcaine, 0.5% and 0.75% solutions should be administered in incremental doses of 3 mL to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. Injections should be made slowly, with frequent aspirations before and during the injection to avoid intravascular injection. Syringe aspirations should also be performed before and during each supplemental injection in continuous (intermittent) catheter techniques. An intravascular injection is still possible even if aspirations for blood are negative.


During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and the effects monitored before the full dose is given. When using a “continuous” catheter technique, test doses should be given prior to both the original and all reinforcing doses, because plastic tubing in the epidural space can migrate into a blood vessel or through the dura. When clinical conditions permit, the test dose should contain epinephrine (10 mcg to 15 mcg has been suggested) to serve as a warning of unintended intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce a transient “epinephrine response” within 45 seconds, consisting of an increase in heart rate and/or systolic blood pressure, circumoral pallor, palpitations, and nervousness in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Therefore, following the test dose, the heart rate should be monitored for a heart rate increase. Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a transient rise in systolic blood pressure. The test dose should also contain 10 mg to 15 mg of Marcaine or an equivalent amount of another local anesthetic to detect an unintended intrathecal administration. This will be evidenced within a few minutes by signs of spinal block (e.g., decreased sensation of the buttocks, paresis of the legs, or, in the sedated patient, absent knee jerk). The Test Dose formulation of Marcaine contains 15 mg of bupivacaine and 15 mcg of epinephrine in a volume of 3 mL. An intravascular or subarachnoid injection is still possible even if results of the test dose are negative. The test dose itself may produce a systemic toxic reaction, high spinal or epinephrine-induced cardiovascular effects.


Injection of repeated doses of local anesthetics may cause significant increases in plasma levels with each repeated dose due to slow accumulation of the drug or its metabolites, or to slow metabolic degradation. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients and acutely ill patients should be given reduced doses commensurate with their age and physical status. Local anesthetics should also be used with caution in patients with hypotension or heartblock.


Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be performed after each local anesthetic injection. It should be kept in mind at such times that restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, depression, or drowsiness may be early warning signs of central nervous system toxicity.


Local anesthetic solutions containing a vasoconstrictor should be used cautiously and in carefully restricted quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply such as digits, nose, external ear, or penis. Patients with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. Ischemic injury or necrosis may result.


Because amide-local anesthetics such as Marcaine are metabolized by the liver, these drugs, especially repeat doses, should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. Local anesthetics should also be used with caution in patients with impaired cardiovascular function because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.


Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are employed in patients during or following the administration of potent inhalation anesthetics. In deciding whether to use these products concurrently in the same patient, the combined action of both agents upon the myocardium, the concentration and volume of vasoconstrictor used, and the time since injection, when applicable, should be taken into account.


Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia. Because it is not known whether amide-type local anesthetics may trigger this reaction and because the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard protocol for management should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure, and metabolic acidosis may precede temperature elevation. Successful outcome is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s) and prompt institution of treatment, including oxygen therapy, indicated supportive measures and dantrolene. (Consult dantrolene sodium intravenous package insert before using.)


Use in Head and Neck Area: Small doses of local anesthetics injected into the head and neck area, including retrobulbar, dental, and stellate ganglion blocks, may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. The injection procedures require the utmost care. Confusion, convulsions, respiratory depression, and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. They may also be due to puncture of the dural sheath of the optic nerve during retrobulbar block with diffusion of any local anesthetic along the subdural space to the midbrain. Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded. (See DOSAGE AND ADMINISTRATION.)


Use in Ophthalmic Surgery: Clinicians who perform retrobulbar blocks should be aware that there have been reports of respiratory arrest following local anesthetic injection. Prior to retrobulbar block, as with all other regional procedures, the immediate availability of equipment, drugs, and personnel to manage respiratory arrest or depression, convulsions, and cardiac stimulation or depression should be assured (see also WARNINGS and Use In Head and Neck Area, above). As with other anesthetic procedures, patients should be constantly monitored following ophthalmic blocks for signs of these adverse reactions, which may occur following relatively low total doses.


A concentration of 0.75% bupivacaine is indicated for retrobulbar block; however, this concentration is not indicated for any other peripheral nerve block, including the facial nerve, and not indicated for local infiltration, including the conjunctiva (see INDICATIONS AND USAGE and PRECAUTIONS, General). Mixing Marcaine with other local anesthetics is not recommended because of insufficient data on the clinical use of such mixtures.


When Marcaine 0.75% is used for retrobulbar block, complete corneal anesthesia usually precedes onset of clinically acceptable external ocular muscle akinesia. Therefore, presence of akinesia rather than anesthesia alone should determine readiness of the patient for surgery.


Use in Dentistry: Because of the long duration of anesthesia, when Marcaine 0.5% with epinephrine is used for dental injections, patients should be cautioned about the possibility of inadvertent trauma to tongue, lips, and buccal mucosa and advised not to chew solid foods or test the anesthetized area by biting or probing.



Information for Patients: When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of caudal or epidural anesthesia. Also, when appropriate, the physician should discuss other information including adverse reactions in the package insert of Marcaine.


Patients receiving dental injections of Marcaine should be cautioned not to chew solid foods or test the anesthetized area by biting or probing until anesthesia has worn off (up to 7 hours).



Clinically Significant Drug Interactions: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.


Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.


Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.



Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate the carcinogenic potential of bupivacaine hydrochloride have not been conducted. The mutagenic potential and the effect on fertility of bupivacaine hydrochloride have not been determined.



Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women.  Marcaine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  Bupivacaine hydrochloride produced developmental toxicity when administered subcutaneously to pregnant rats and rabbits at clinically relevant doses.  This does not exclude the use of Marcaine at term for obstetrical anesthesia or analgesia. (See Labor and Delivery)


Bupivacaine hydrochloride was administered subcutaneously to rats at doses of 4.4, 13.3, & 40 mg/kg and to rabbits at doses of 1.3, 5.8, & 22.2 mg/kg during the period of organogenesis (implantation to closure of the hard palate).  The high doses are comparable to the daily maximum recommended human dose (MRHD) of 400 mg/day on a mg/m2 body surface area (BSA) basis.  No embryo-fetal effects were observed in rats at the high dose which caused increased maternal lethality.  An increase in embryo-fetal deaths was observed in rabbits at the high dose in the absence of maternal toxicity with the fetal No Observed Adverse Effect Level representing approximately 1/5th the MRHD on a BSA basis.


In a rat pre- and post-natal development study (dosing from implantation through weaning) conducted at subcutaneous doses of 4.4, 13.3, & 40 mg/kg mg/kg/day, decreased pup survival was observed at the high dose.  The high dose is comparable to the daily MRHD of 400 mg/day on a BSA basis.



Labor and Delivery: SEE BOXED WARNING REGARDING OBSTETRlCAL USE OF 0.75% Marcaine.


Marcaine is contraindicated for obstetrical paracervical block anesthesia.


Local anesthetics rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity. (See CLINICAL PHARMACOLOGY, Pharmacokinetics.) The incidence and degree of toxicity depend upon the procedure performed, the type, and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus, and neonate involve alterations of the central nervous system, peripheral vascular tone, and cardiac function.


Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient’s legs and positioning her on her left side will help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable.


Epidural, caudal, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. Epidural anesthesia has been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.


The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. This has not been reported with bupivacaine.


It is extremely important to avoid aortocaval compression by the gravid uterus during administration of regional block to parturients. To do this, the patient must be maintained in the left lateral decubitus position or a blanket roll or sandbag may be placed beneath the right hip and gravid uterus displaced to the left.



Nursing Mothers: Bupivacaine has been reported to be excreted in human milk suggesting that the nursing infant could be theoretically exposed to a dose of the drug. Because of the potential for serious adverse reactions in nursing infants from bupivacaine, a decision should be made whether to discontinue nursing or not administer bupivacaine, taking into account the importance of the drug to the mother.



Pediatric Use: Until further experience is gained in pediatric patients younger than 12 years, administration of Marcaine in this age group is not recommended. Continuous infusions of bupivacaine in children have been reported to result in high systemic levels of bupivacaine and seizures; high plasma levels may also be associated with cardiovascular abnormalities. (See WARNINGS, PRECAUTIONS, and OVERDOSAGE.)



Geriatric Use: Patients over 65 years, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing anesthesia with Marcaine. (See ADVERSE REACTIONS.)


Elderly patients may require lower doses of Marcaine. (See PRECAUTIONS, Epidural Anesthesia and DOSAGE AND ADMINISTRATION.)


In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients. (See CLINICAL PHARMACOLOGY.)


This product is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY.)



Adverse Reactions


Reactions to Marcaine are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation.


The most commonly encountered acute adverse experiences which demand immediate counter-measures are related to the central nervous system and the cardiovascular system. These adverse experiences are generally dose related and due to high plasma levels which may result from overdosage, rapid absorption from the injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution. In addition to systemic dose-related toxicity, unintentional subarachnoid injection of drug during the intended performance of caudal or lumbar epidural block or nerve blocks near the vertebral column (especially in the head and neck region) may result in underventilation or apnea (“Total or High Spinal”). Also, hypotension due to loss of sympathetic tone and respiratory paralysis or underventilation due to cephalad extension of the motor level of anesthesia may occur. This may lead to secondary cardiac arrest if untreated. Patients over 65 years, particularly those with hypertension, may be at increased risk for experiencing the hypotensive effects of Marcaine. Factors influencing plasma protein binding, such as acidosis, systemic diseases which alter protein production, or competition of other drugs for protein binding sites, may diminish individual tolerance.



Central Nervous System Reactions: These are characterized by excitation and/or depression. Restlessness, anxiety, dizziness, tinnitus, blurred vision, or tremors may occur, possibly proceeding to convulsions. However, excitement may be transient or absent, with depression being the first manifestation of an adverse reaction. This may quickly be followed by drowsiness merging into unconsciousness and respiratory arrest. Other central nervous system effects may be nausea, vomiting, chills, and constriction of the pupils.


The incidence of convulsions associated with the use of local anesthetics varies with the procedure used and the total dose administered. In a survey of studies of epidural anesthesia, overt toxicity progressing to convulsions occurred in approximately 0.1% of local anesthetic administrations.



Cardiovascular System Reactions: High doses or unintentional intravascular injection may lead to high plasma levels and related depression of the myocardium, decreased cardiac output, heartblock, hypotension, bradycardia, ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation, and cardiac arrest. (See WARNINGS, PRECAUTIONS, and OVERDOSAGE.)



Allergic: Allergic-type reactions are rare and may occur as a result of sensitivity to the local anesthetic or to other formulation ingredients, such as the antimicrobial preservative methylparaben contained in multiple-dose vials or sulfites in epinephrine-containing solutions. These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid-like symptomatology (including severe hypotension). Cross sensitivity among members of the amide-type local anesthetic group has been reported. The usefulness of screening for sensitivity has not been definitely established.



Neurologic: The incidences of adverse neurologic reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient. Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug.


In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter or needle may occur. Subsequent adverse effects may depend partially on the amount of drug administered intrathecally and the physiological and physical effects of a dural puncture. A high spinal is characterized by paralysis of the legs, loss of consciousness, respiratory paralysis, and bradycardia.


Neurologic effects following epidural or caudal anesthesia may include spinal block of varying magnitude (including high or total spinal block); hypotension secondary to spinal block; urinary retention; fecal and urinary incontinence; loss of perineal sensation and sexual function; persistent anesthesia, paresthesia, weakness, paralysis of the lower extremities and loss of sphincter control all of which may have slow, incomplete, or no recovery; headache; backache; septic meningitis; meningismus; slowing of labor; increased incidence of forceps delivery; and cranial nerve palsies due to traction on nerves from loss of cerebrospinal fluid.


Neurologic effects following other procedures or routes of administration may include persistent anesthesia, paresthesia, weakness, paralysis, all of which may have slow, incomplete, or no recovery.



Overdosage


Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution. (See ADVERSE REACTIONS, WARNINGS, and PRECAUTIONS.)



Management of Local Anesthetic Emergencies: The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered.


The first step in the management of systemic toxic reactions, as well as underventilation or apnea due to unintentional subarachnoid injection of drug solution, consists of immediate attention to the establishment and maintenance of a patent airway and effective assisted or controlled ventilation with 100% oxygen with a delivery system capable of permitting immediate positive airway pressure by mask. This may prevent convulsions if they have not already occurred.


If necessary, use drugs to control the convulsions. A 50 mg to 100 mg bolus IV injection of succinylcholine will paralyze the patient without depressing the central nervous or cardiovascular systems and facilitate ventilation. A bolus IV dose of 5 mg to 10 mg of diazepam or 50 mg to 100 mg of thiopental will permit ventilation and counteract central nervous system stimulation, but these drugs also depress central nervous system, respiratory, and cardiac function, add to postictal depression and may result in apnea. Intravenous barbiturates, anticonvulsant agents, or muscle relaxants should only be administered by those familiar with their use. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated. Supportive treatment of circulatory depression may require administration of intravenous fluids, and when appropriate, a vasopressor dictated by the clinical situation (such as ephedrine or epinephrine to enhance myocardial contractile force).


Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated after initial administration of oxygen by mask if difficulty is encountered in the maintenance of a patent airway, or if prolonged ventilatory support (assisted or controlled) is indicated.


Recent clinical data from patients experiencing local anesthetic-induced convulsions demonstrated rapid development of hypoxia, hypercarbia, and acidosis with bupivacaine within a minute of the onset of convulsions. These observations suggest that oxygen consumption and carbon dioxide production are greatly increased during local anesthetic convulsions and emphasize the importance of immediate and effective ventilation with oxygen which may avoid cardiac arrest.


If not treated immediately, convulsions with simultaneous hypoxia, hypercarbia, and acidosis plus myocardial depression from the direct effects of the local anesthetic may result in cardiac arrhythmias, bradycardia, asystole, ventricular fibrillation, or cardiac arrest. Respiratory abnormalities, including apnea, may occur. Underventilation or apnea due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted. If cardiac arrest should occur, successful outcome may require prolonged resuscitative efforts.


The supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus. Therefore during treatment of systemic toxicity, maternal hypotension or fetal bradycardia following regional block, the parturient should be maintained in the left lateral decubitus position if possible, or manual displacement of the uterus off the great vessels be accomplished.


The mean seizure dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL. The intravenous and subcutaneous LD50 in mice is 6 mg/kg to 8 mg/kg and 38 mg/kg to 54 mg/kg respectively.



Marcaine Dosage and Administration


The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. The smallest dose and concentration required to produce the desired result should be administered. Dosages of Marcaine should be reduced for elderly and/or debilitated patients and patients with cardiac and/or liver disease. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should be used when feasible.


For specific techniques and procedures, refer to standard textbooks.


There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures.  Marcaine is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION).


In recommended doses, Marcaine produces complete sensory block, but the effect on motor function differs among the three concentrations.



0.25%—when used for caudal, epidural, or peripheral nerve block, produces incomplete motor block. Should be used for operations in which muscle relaxation is not important, or when another means of providing muscle relaxation is used concurrently. Onset of action may be slower than with the 0.5% or 0.75% solutions.


0.5%— provides motor blockade for caudal, epidural, or nerve block, but muscle relaxation may be inadequate for operations in which complete muscle relaxation is essential.


0.75%—produces complete motor block. Most useful for epidural block in abdominal operations requiring complete muscle relaxation, and for retrobulbar anesthesia. Not for obstetrical anesthesia.



The duration of anesthesia with Marcaine is such that for most indications, a single dose is sufficient.


Maximum dosage limit must be individualized in each case after evaluating the size and physical status of the patient, as well as the usual rate of systemic absorption from a particular injection site. Most experience to date is with single doses of Marcaine up to 225 mg with epinephrine 1:200,000 and 175 mg without epinephrine; more or less drug may be used depending on individualization of each case.


These doses may be repeated up to once every three hours. In clinical studies to date, total daily doses have been up to 400 mg. Until further experience is gained, this dose should not be exceeded in 24 hours. The duration of anesthetic effect may be prolonged by the addition of epinephrine.


The dosages in Table 1 have generally proved satisfactory and are recommended as a guide for use in the average adult. These dosages should be reduced for elderly or debilitated patients. Until further experience is gained, Marcaine is not recommended for pediatric patients younger than 12 years. Marcaine is contraindicated for obstetrical paracervical blocks, and is not recommended for intravenous regional anesthesia (Bier Block).


Use in Epidural Anesthesia: During epidural administration of Marcaine, 0.5% and 0.75% solutions should be administered in incremental doses of 3 mL to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. In obstetrics, only the 0.5% and 0.25% concentrations should be used; incremental doses of 3 mL to 5 mL of the 0.5% solution not exceeding 50 mg to 100 mg at any dosing interval are recommended. Repeat doses should be preceded by a test dose containing epinephrine if not contraindicated. Use only the single-dose ampuls and single-dose vials for caudal or epidural anesthesia; the multiple-dose vials contain a preservative and therefore should not be used for these procedures.


Test Dose for Caudal and Lumbar Epidural Blocks: The Test Dose of Marcaine (0.5% bupivacaine with 1:200,000 epinephrine in a 3 mL ampul) is recommended for use as a test dose when clinical conditions permit prior to caudal and lumbar epidural blocks. This may serve as a warning of unintended intravascular or subarachnoid injection. (See PRECAUTIONS.) The pulse rate and other signs should be monitored carefully immediately following each test dose administration to detect possible intravascular injection, and adequate time for onset of spinal block should be allotted to detect possible intrathecal injection. An intravascular or subarachnoid injection is still possible even if results of the test dose are negative. The test dose itself may produce a systemic toxic reaction, high spinal or cardiovascular effects from the epinephrine. (See WARNINGS and OVERDOSAGE.)


Use in Dentistry: The 0.5% concentration with epinephrine is recommended for infiltration and block injection in the maxillary and mandibular area when a longer duration of local anesthetic action is desired, such as for oral surgical procedures generally associated with significant postoperative pain. The average dose of 1.8 mL (9 mg) per injection site will usually suffice; an occasional second dose of 1.8 mL (9 mg) may be used if necessary to produce adequate anesthesia after making allowance for 2 to 10 minutes onset time. (See CLINICAL PHARMACOLOGY.) The lowest effective dose should be employed and time should be allowed between injections; it is recommended that the total dose for all injection sites, spread out over a single dental sitting, should not ordinarily exceed 90 mg for a healthy adult patient (ten 1.8 mL injections of 0.5% Marcaine with epinephrine). Injections should be made slowly and with frequent aspirations. Until further experience is gained, Marcaine in dentistry is not recommended for pediatric patients younger than 12 years.


Unused portions of solution not containing preservatives, i.e., those supplied in single-dose ampuls and single-dose vials, should be discarded following initial use.


This product should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Solutions which are discolored or which contain particulate matter should not be administered.




Table 1. Recommended Concentrations and Doses of Marcaine